Median progression-free survival ( months ) was 9.7 ( 95 % CI , 8.5-11 .0 ; 61 events ) for mutation-positive tumor and 10.2 ( 95 % CI , 8.5-12 .5 ; 36 events ) for mutation-positive tumor and plasma 1 .